United Therapeutics

United Therapeutics: FDA Approves Tyvaso For PH-ILD
United Therapeutics: FDA Approves Tyvaso For PH-ILD
NASDAQ
United Therapeutics
FDA
Tyvaso
PH-ILD
pulmonary hypertension
Flag link:
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback
Endpoints
United Therapeutics
Trevyent
PAH
SteadyMed
Flag link:
Corporate and regulatory developments over the holidays
Corporate and regulatory developments over the holidays
EP Vantage
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Flag link:
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso
Endpoints
United Therapeutics
Tyvaso
priority review voucher
PAH
Flag link:
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
Xconomy
United Therapeutics
clinical trials
Unituxin
small cell lung cancer
Flag link:
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Fierce Pharma
Novartis
Sandoz
United Therapeutics
Remodulin
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
EP Vantage
United Therapeutics
Unituxin
SCLC
Biogen
MAb BIIB092
Flag link:
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
United Therapeutics Fires Back After Sandoz Files Anti-Competitive Lawsuit Over PAH Drug
BioSpace
United Therapeutics
PAH
Remodulin
generics
Sandoz
Flag link:
United Therapeutics tosses out esuberaprost after trial flop
United Therapeutics tosses out esuberaprost after trial flop
Fierce Biotech
United Therapeutics
PAH
esuberaprost
clinical trials
Flag link:
Arena’s Comeback Continues with $800M Deal for Blood Disease Drug
Arena’s Comeback Continues with $800M Deal for Blood Disease Drug
Xconomy
Arena Pharmaceuticals
United Therapeutics
PAH
ralinepag
Flag link:
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil
Endpoints
MannKind
United Therapeutics
PAH
Treprostinil
Flag link:
Mylan Launches First Adcirca Generic, Stock Moves Up
Mylan Launches First Adcirca Generic, Stock Moves Up
Market Realist
Mylan
tadalafil
generics
PAH
Adcirca
United Therapeutics
Flag link:
Medtronic wins FDA nod to deliver PAH therapy with implantable pump
Medtronic wins FDA nod to deliver PAH therapy with implantable pump
Drug Delivery Business News
Medtronic
FDA
drug delivery
United Therapeutics
PAH
Remodulin
devices
SynchroMed II
Flag link:
GSK-backed Liquidia takes a seat at the IPO table, looking for a $57.5M stake to take on United Therapeutics
GSK-backed Liquidia takes a seat at the IPO table, looking for a $57.5M stake to take on United Therapeutics
Endpoints
Liquidia
IPOs
PAH
United Therapeutics
Tyvaso
Flag link:
United Therapeutics pays $210M to resolve kickback probe
United Therapeutics pays $210M to resolve kickback probe
BioPharma Dive
United Therapeutics
kickbacks
DOJ
False Claims Act
Flag link:
Gilead Could Be Making An Acquisition — But It's Not What You Think
Gilead Could Be Making An Acquisition — But It's Not What You Think
Investors Business Daily
Gilead Sciences
M&A
United Therapeutics
GSK
Novartis
Flag link:
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
Yahoo/Zacks.com
United Therapeutics
earnings
Flag link:
How Is United Therapeutics’ Remodulin Positioned in 2017?
How Is United Therapeutics’ Remodulin Positioned in 2017?
Market Realist
United Therapeutics
Remodulin
PAH
pulmonary arterial hypertension
Flag link:
The 3 Most Profit-Friendly Biotech Stocks
The 3 Most Profit-Friendly Biotech Stocks
Motley Fool
biotech
biotech stocks
United Therapeutics
Gilead Sciences
Biogen
Flag link:

Pages